Crimean-Congo Hemorrhagic Fever-Treatment and Preventive Strategies

AuthorMaryam Keshtkar Jahromien
Issued Date2014-07-30en
AbstractCrimean-Congo hemorrhagic fever is a tick-borne viral disease reported from more than 30 countries in Africa, Asia, South-East Europe, and the Middle East. The majority of human cases are workers in livestock industry, agriculture, slaughterhouses, and veterinary practice. The current mortality rate in endemic areas varies between 5 to 20 percent depending on the geographic location and medical supportive treatment. Unfortunately, there is currently no FDA-approved vaccine for prevention or specific antiviral drug for the treatment of CCHF. Ribavirin, effective against CCHFV in vitro, is one of the few options for treatment of CCHFV, but its efficacy is still questionable due to contradictory clinical studies. The efficacy of other options including Intravenous Immuneglobulin (IVIG), steroids, CCHF hyperimmuneglobulin, and CCHF monoclonal antibodies is still controversial.en
DOIhttps://doi.org/10.17795/iji-20310en
KeywordHemorrhagic Feveren
KeywordCrimeanen
KeywordTherapeuticsen
Keywordprevention and Controlen
PublisherBrieflandsen
TitleCrimean-Congo Hemorrhagic Fever-Treatment and Preventive Strategiesen
TypeReview Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
14690-pdf.pdf
Size:
81.03 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF